Immunis Welcomes Dr. Peter Diamandis to the Executive Advisory Board

IRVINE, Calif. , Sept. 20, 2022 /PRNewswire/ -- Immunis Inc., a private biotechnology company developing an immunomodulatory secretome for age and disease-related immune decline in Phase 1/2a testing, welcomes Peter H. Diamandis, M.D. to the Executive Advisory Board. Dr. Diamandis...

Click to view original post